GB0814466D0 - Sertraline composition - Google Patents

Sertraline composition

Info

Publication number
GB0814466D0
GB0814466D0 GBGB0814466.9A GB0814466A GB0814466D0 GB 0814466 D0 GB0814466 D0 GB 0814466D0 GB 0814466 A GB0814466 A GB 0814466A GB 0814466 D0 GB0814466 D0 GB 0814466D0
Authority
GB
United Kingdom
Prior art keywords
sertraline composition
sertraline
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0814466.9A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rosemont Pharmaceuticals Ltd
Original Assignee
Rosemont Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rosemont Pharmaceuticals Ltd filed Critical Rosemont Pharmaceuticals Ltd
Priority to GBGB0814466.9A priority Critical patent/GB0814466D0/en
Publication of GB0814466D0 publication Critical patent/GB0814466D0/en
Priority to GB1102349.6A priority patent/GB2474209B/en
Priority to PCT/GB2009/001700 priority patent/WO2010015797A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
GBGB0814466.9A 2008-08-07 2008-08-07 Sertraline composition Ceased GB0814466D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB0814466.9A GB0814466D0 (en) 2008-08-07 2008-08-07 Sertraline composition
GB1102349.6A GB2474209B (en) 2008-08-07 2009-07-08 Sertraline composition
PCT/GB2009/001700 WO2010015797A1 (en) 2008-08-07 2009-07-08 Sertraline composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0814466.9A GB0814466D0 (en) 2008-08-07 2008-08-07 Sertraline composition

Publications (1)

Publication Number Publication Date
GB0814466D0 true GB0814466D0 (en) 2008-09-10

Family

ID=39767674

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB0814466.9A Ceased GB0814466D0 (en) 2008-08-07 2008-08-07 Sertraline composition
GB1102349.6A Active GB2474209B (en) 2008-08-07 2009-07-08 Sertraline composition

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB1102349.6A Active GB2474209B (en) 2008-08-07 2009-07-08 Sertraline composition

Country Status (2)

Country Link
GB (2) GB0814466D0 (en)
WO (1) WO2010015797A1 (en)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT768083E (en) * 1995-07-17 2003-08-29 Pfizer SERCALINE FOR THE TREATMENT OF PATIENTS MYOCARDIAL POS-FRAGMENT
BR9911068A (en) * 1998-05-29 2001-02-06 Lilly Co Eli Combination therapy for the treatment of bipolar disorders
US20050070577A1 (en) * 2003-07-03 2005-03-31 Pfizer Inc. Compositions containing a serotonin selective reuptake inhibitor and a 5-HT2A receptor antagonist
EP1742535A4 (en) * 2004-05-06 2008-10-15 Cydex Pharmaceuticals Inc Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin
WO2007087387A1 (en) * 2006-01-23 2007-08-02 Teva Pharmaceutical Industries Ltd. A recycling process for preparing sertraline
EP2018160B1 (en) * 2006-03-16 2011-12-14 Tris Pharma, Inc. Modified release formulations containing drug-ion exchange resin complexes
WO2008020150A1 (en) * 2006-08-18 2008-02-21 Syngenta Limited Use of hppd inhibitors in the treatment of depression and/or withdrawal symptoms associated with addictive drugs

Also Published As

Publication number Publication date
GB2474209A (en) 2011-04-06
GB201102349D0 (en) 2011-03-30
WO2010015797A1 (en) 2010-02-11
GB2474209B (en) 2012-02-22

Similar Documents

Publication Publication Date Title
GB0815022D0 (en) Composition
GB0819633D0 (en) Composition
GB0822246D0 (en) Composition
GB0801119D0 (en) Composition
GB0818473D0 (en) Composition
GB0810554D0 (en) Herbicde composition
GB0809808D0 (en) Composition
GB0818472D0 (en) Composition
GB0811743D0 (en) Composition
GB0801401D0 (en) Composition
EP2357204A4 (en) Composition
GB0810359D0 (en) Composition
GB0817656D0 (en) Composition
GB0812740D0 (en) Composition
GB0806948D0 (en) Composition
GB0818269D0 (en) Composition
GB0813589D0 (en) Composition
GB0809983D0 (en) Composition
GB0903681D0 (en) Composition
GB0823344D0 (en) Composition
GB0821754D0 (en) Composition
GB0818231D0 (en) Composition
GB0820259D0 (en) Composition
GB0818336D0 (en) Composition
GB0814101D0 (en) Composition

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)